Provided by Tiger Trade Technology Pte. Ltd.

Cytosorbents

0.5930
-0.0071-1.18%
Post-market: 0.59300.00000.00%16:00 EDT
Volume:158.44K
Turnover:93.03K
Market Cap:37.24M
PE:-3.48
High:0.6200
Open:0.6200
Low:0.5501
Close:0.6001
52wk High:1.39
52wk Low:0.4992
Shares:62.80M
Float Shares:54.98M
Volume Ratio:1.27
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1705
EPS(LYR):-0.3806
ROE:-96.39%
ROA:-19.44%
PB:6.31
PE(LYR):-1.56

Loading ...

Cytosorbents’ Earnings Call Balances Progress and Risk

TIPRANKS
·
Mar 27

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 27

Cytosorbents Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

CytoSorbents 2025 revenue rises, net loss narrows

Reuters
·
Mar 26

CytoSorbents Q4 Adj. EPS $(0.07) Misses $(0.05) Estimate, Sales $9.234M Miss $9.587M Estimate

Benzinga
·
Mar 26

CytoSorbents FY2025 net loss narrows to $8 million; revenue rises 4% to $37.1 million

Reuters
·
Mar 26

Cytosorbents FY EPS USD -0.13

THOMSON REUTERS
·
Mar 26

Cytosorbents Corp expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
Mar 24

CytoSorbents Hosts ISICEM 2026 Symposium in Brussels

Reuters
·
Mar 19

CytoSorbents Corporation updates financial calendar with upcoming earnings report and webcast

Reuters
·
Mar 05

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 12

BRIEF-CytoSorbents FY Revenue USD 37 Million

Reuters
·
Jan 12

Cytosorbents FY Revenue USD 37 Million

THOMSON REUTERS
·
Jan 12

Cytosorbents Corp - Drugsorb-Atr FDA Meeting Scheduled, Decision Expected Mid-2026

THOMSON REUTERS
·
Jan 12

Cytosorbents FY Product Gross Margin 72%

THOMSON REUTERS
·
Jan 12

Press Release: CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

Dow Jones
·
Jan 12

Cytosorbents Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Dec 17, 2025

CytoSorbents Corporation Leadership Joins D. Boral Capital for Virtual Fireside Chat

Reuters
·
Dec 10, 2025

CytoSorbents CEO Phillip P. Chan Reports Acquisition of Common Shares

Reuters
·
Nov 21, 2025

CytoSorbents Q3 Revenue USD 9.485 Million

Reuters
·
Nov 20, 2025